MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-27-2024
Ampio Pharmaceuticals Total Liabilities 2011-2026 | AMPE
Annual Total Liabilities Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.38 M | 1.8 M | 11.5 M | 5.37 M | 7.56 M | 8.79 M | 49.5 M | 6.96 M | 12.5 M | 4.81 M | 2.8 M | 2.02 M | 1.72 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 49.5 M | 1.72 M | 9.06 M |
Quarterly Total Liabilities Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.27 M | 2.59 M | 2.86 M | 1.8 M | 4.99 M | 7.12 M | 10.5 M | 11.5 M | 5.2 M | 6.35 M | 4.95 M | 5.37 M | 5.37 M | 5.37 M | 5.37 M | 7.56 M | 7.56 M | 7.56 M | 7.56 M | 8.79 M | 8.79 M | 8.79 M | 8.79 M | 49.5 M | 49.5 M | 49.5 M | 49.5 M | 6.96 M | 6.96 M | 6.96 M | 6.96 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 4.81 M | 4.81 M | 4.81 M | 4.81 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.02 M | 2.02 M | 2.02 M | 2.02 M | 1.72 M | 1.72 M | 1.72 M | 1.72 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49.5 M | 1.72 M | 9.18 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 0.82 | -3.48 % | $ 4.47 M |  China |
 |
Rigel Pharmaceuticals
RIGL
|
122 M | $ 33.23 | -4.03 % | $ 584 M |  USA |
 |
Graybug Vision
GRAY
|
20.2 M | - | -11.23 % | $ 9.65 M | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Apellis Pharmaceuticals
APLS
|
705 M | $ 20.15 | -2.68 % | $ 2.54 B | USA |
 |
AbCellera Biologics
ABCL
|
390 M | $ 3.72 | -2.75 % | $ 1.11 B |  Canada |
 |
Athersys
ATHX
|
28.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
59.5 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
602 M | $ 163.7 | -1.61 % | $ 8.14 B | USA |
 |
BridgeBio Pharma
BBIO
|
3.01 B | $ 64.66 | -1.37 % | $ 12.4 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
9.6 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 8.52 | -2.46 % | $ 1.39 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
276 M | - | - | $ 789 M | USA |
 |
Certara
CERT
|
494 M | $ 7.16 | 1.49 % | $ 1.15 B | USA |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
5.68 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
752 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
Capricor Therapeutics
CAPR
|
36.1 M | $ 25.91 | -3.56 % | $ 694 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
150 M | $ 24.0 | 0.5 % | $ 2.93 B | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
82.1 M | $ 0.99 | -3.28 % | $ 72.7 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
6.87 M | $ 17.75 | -0.79 % | $ 852 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
144 M | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
1.03 M | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
6.27 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
6.27 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
123 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
Denali Therapeutics
DNLI
|
144 M | $ 20.02 | -4.67 % | $ 3.29 B | USA |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Eton Pharmaceuticals
ETON
|
16.3 M | $ 17.54 | -3.36 % | $ 450 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
9.71 M | - | - | $ 105 M | USA |
 |
Evofem Biosciences
EVFM
|
72.5 M | - | 7.55 % | $ 38.1 M | USA |